Shah Pritik A, Hasan Mohammad Mehedi, Sahito Abdul Moiz, Patel Suyog Y, Ramproshad Sarker, Mondal Banani, Essar Mohammad Yasir
Bangalore Medical College and Research Institute, Bangalore, India.
Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh.
Ann Med Surg (Lond). 2022 Jul;79:104011. doi: 10.1016/j.amsu.2022.104011. Epub 2022 Jun 18.
Recently, the World Health Organization (WHO) approved RTS, S/AS01 (RTS, S) as the world's first malaria vaccine for partial malaria protection in young children at risk. While this immunization drive begins during the unprecedented pandemic of the SARS-CoV-2 Virus, the WHO has also approved 7 Vaccines in 2021 for the vaccination of children at risk. This article explores the quandary that would occur to the officials in charge of carrying out large vaccination campaigns against these two deadly infectious illnesses in several regions including the continent of Africa. The article also outlines the priorities for resolving this dilemma, offers evidence-based solutions, and provides a summary of recent significant events and their consequences. While providing the latest data, a discussion on the causation of the dilemma with clear recommendations for possible solutions has been explored as well.
最近,世界卫生组织(WHO)批准了RTS,S/AS01(RTS,S)作为全球首款用于为有感染风险的幼儿提供部分疟疾防护的疟疾疫苗。在这一免疫接种行动启动之际,正值严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒肆虐的前所未有的大流行期间,世卫组织还在2021年批准了7种疫苗用于为有风险的儿童接种。本文探讨了在包括非洲大陆在内的几个地区负责开展针对这两种致命传染病的大规模疫苗接种运动的官员将会面临的困境。文章还概述了解决这一困境的优先事项,提供了基于证据的解决方案,并总结了近期的重大事件及其后果。在提供最新数据的同时,还探讨了对这一困境成因的讨论以及针对可能解决方案的明确建议。